Since PHLDA3 regulates the PI3K/Akt/mTOR pathway by suppressing Akt activation, it is possible that new drugs that mimic PHLDA3 function may show efficacy not only in PanNETs but also in other cancers in which Akt is highly activated. Here, AKT1 is linked to cancer.